Concurrent treatment with antogmiR-21 and IM increased the efficacy of IM and apoptosis of CD34+ CML cells without affecting normal CD34+ cells [54].The authors concluded that antagonizing miR-21 increases efficacy of IM on LSCs by targeting the PI3K/AKT pathway. The gene discussed is AKT1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.